Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 373-377

  Okamoto, Yoshihisa ^a,b   Ishii, So ^a   Croce, Kevin ^c   Katsumata, Harumi ^a   Fukushima, Makoto ^a   Kihara, Shinji ^d   Libby, Peter ^c   Minami, Shiro ^a,b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Atherothrombosis; Macrophage; Tissue factor

Indexed keywords

LIPOPOLYSACCHARIDE; MESSENGER RNA; RECOMBINANT ADIPONECTIN; RECOMBINANT PROTEIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING TEST; CELL LYSATE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; MACROPHAGE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; THROMBOSIS;

ADIPONECTIN; ANIMALS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; PLAQUE, ATHEROSCLEROTIC; RNA, MESSENGER; THROMBOPLASTIN;

EID: 84872420425     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.12.012     Document Type: Article

References (30)

1. Matsuzawa Y., Funahashi T., Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011, 18:629-639.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.
3. Okamoto Y., Kihara S., Funahashi T., et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006, 110:267-278.
4. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
5. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:134-141.
6. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
7. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
8. Komura N., Kihara S., Sonoda M., et al. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J 2008, 72:23-28.
9. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623-629.
10. Sattar N., Watt P., Cherry L., et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J Clin Endocrinol Metab 2008, 93:1846-1849.
11. Okamoto Y., Arita Y., Nishida M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000, 32:47-50.
12. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
13. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
14. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
15. Okamoto Y., Folco E.J., Minami M., et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008, 102:218-225.
16. Nawrocki A.R., Hofmann S.M., Teupser D., et al. Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2010, 30:1159-1165.
17. Otsuka F., Sugiyama S., Kojima S., et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 2006, 48:1155-1162.
18. Wolk R., Berger P., Lennon R.J., et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007, 28:292-298.
19. Nakagawa Y., Kishida K., Mazaki T., et al. Impact of sleep-disordered breathing, visceral fat accumulation and adiponectin levels in patients with night-time onset of acute coronary syndrome. Am J Cardiol 2011, 108:1266-1271.
20. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004, 24:1015-1022.
21. Mackman N., Brand K., Edgington T.S. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J Exp Med 1991, 174:1517-1526.
22. Marx N., Mach F., Sauty A., et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000, 164:6503-6508.
23. Drake T.A., Ruf W., Morrissey J.H., et al. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989, 109:389-395.
24. Guha M., O'Connell M.A., Pawlinski R., et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001, 98:1429-1439.
25. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
26. Kumada M., Kihara S., Ouchi N., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109:2046-2049.
27. Matsuura F., Oku H., Koseki M., et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007, 358:1091-1095.
28. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
29. Kato H., Kashiwagi H., Shiraga M., et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006, 26:224-230.
30. Chen Y.J., Zhang L.Q., Wang G.P., et al. Adiponectin inhibits tissue factor expression and enhances tissue factor pathway inhibitor expression in human endothelial cells. Thromb Haemost 2008, 100:291-300.